120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
MYH9相关疾病中血小板膜糖蛋白及特异性抗体分析
Authors Wang L , Cao K, Chen S, Fu X, Chen Y, Luo X
Received 1 August 2025
Accepted for publication 10 January 2026
Published 21 January 2026 Volume 2026:19 538585
DOI https://doi.org/10.2147/IJGM.S538585
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor David E. Stec
Lin Wang,1,2,* Ke Cao,3,* Shiyang Chen,3 Xiaoying Fu,3 Yunsheng Chen,3 Xiaojuan Luo1,3
1Shantou University School of Medicine, Shantou, Guangdong, 515000, People’s Republic of China; 2Department of Clinical Laboratory, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, 518038, People’s Republic of China; 3Department of Clinical Laboratory, Shenzhen Children’s Hospital, Shenzhen, Guangdong, 518038, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaojuan Luo, Department of Clinical Laboratory, Shenzhen Children’s Hospital, Shenzhen, Guangdong, People’s Republic of China, Email luoxiaojuan1983@126.com
Objective: To comparatively analyze platelet membrane glycoprotein expression profiles and antiplatelet-specific antibody levels in patients with MYH9-related disorders (MYH9-RD) versus immune thrombocytopenia (ITP), and to evaluate their potential clinical significance.
Methods: From July 2017 to June 2025, a total of 20 patients with MYH9-RD, 20 patients with ITP, and 20 healthy controls were enrolled. Platelet membrane glycoprotein expression of CD41 (GPIIb), CD42a (GPIX), CD42b (GPIb), CD61 (GPIIIa), and CD62P (GMP140), platelet-leukocyte aggregation ratios, and antiplatelet-specific antibody levels were analyzed using flow cytometry. Inter-group differences in platelet membrane glycoprotein expression were compared using the Kruskal–Wallis test.
Results: The MYH9-RD cohort demonstrated significantly higher median fluorescence intensity of platelet membrane glycoproteins (CD41, CD42a, CD42b, CD61, and CD62P) compared to ITP and healthy control groups (P < 0.05). Compared to ITP patients, the MYH9-RD group demonstrated significantly higher platelet-leukocyte (P = 0.020) and platelet-granulocyte aggregation ratios (P = 0.004), as quantified by flow cytometry. The identified MYH9-RD mutations were localized to both N-terminal and C-terminal regions of the NMMHC-IIA protein domain. However, no statistically significant differences in platelet membrane glycoprotein expression profiles were observed between the two groups (P > 0.05). Significant intergroup differences (P < 0.05) were observed in the detection rates of antiplatelet antibodies targeting GPIX, GPIb, GPIIb, GPIIIa, and P-selectin (GMP140) among MYH9-RD, ITP, and healthy control groups. The total antibody positivity rate in MYH9-RD patients was intermediate—significantly higher than in healthy controls (P = 0.0317) but lower than in ITP patients (P = 0.0017).
Conclusion: Significant differences in platelet membrane glycoprotein expression profiles and antiplatelet-specific antibody levels distinguish MYH9-related disorders (MYH9-RD) from immune thrombocytopenia (ITP). These findings have important clinical implications, providing potential biomarkers for the differential diagnosis of MYH9-RD.
Keywords: MYH9-RD, thrombocytopenia, platelet membrane glycoprotein, antiplatelet specific antibodies
1Shantou University School of Medicine, Shantou, Guangdong, 515000, People’s Republic of China; 2Department of Clinical Laboratory, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, 518038, People’s Republic of China; 3Department of Clinical Laboratory, Shenzhen Children’s Hospital, Shenzhen, Guangdong, 518038, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaojuan Luo, Department of Clinical Laboratory, Shenzhen Children’s Hospital, Shenzhen, Guangdong, People’s Republic of China, Email luoxiaojuan1983@126.com
Objective: To comparatively analyze platelet membrane glycoprotein expression profiles and antiplatelet-specific antibody levels in patients with MYH9-related disorders (MYH9-RD) versus immune thrombocytopenia (ITP), and to evaluate their potential clinical significance.
Methods: From July 2017 to June 2025, a total of 20 patients with MYH9-RD, 20 patients with ITP, and 20 healthy controls were enrolled. Platelet membrane glycoprotein expression of CD41 (GPIIb), CD42a (GPIX), CD42b (GPIb), CD61 (GPIIIa), and CD62P (GMP140), platelet-leukocyte aggregation ratios, and antiplatelet-specific antibody levels were analyzed using flow cytometry. Inter-group differences in platelet membrane glycoprotein expression were compared using the Kruskal–Wallis test.
Results: The MYH9-RD cohort demonstrated significantly higher median fluorescence intensity of platelet membrane glycoproteins (CD41, CD42a, CD42b, CD61, and CD62P) compared to ITP and healthy control groups (P < 0.05). Compared to ITP patients, the MYH9-RD group demonstrated significantly higher platelet-leukocyte (P = 0.020) and platelet-granulocyte aggregation ratios (P = 0.004), as quantified by flow cytometry. The identified MYH9-RD mutations were localized to both N-terminal and C-terminal regions of the NMMHC-IIA protein domain. However, no statistically significant differences in platelet membrane glycoprotein expression profiles were observed between the two groups (P > 0.05). Significant intergroup differences (P < 0.05) were observed in the detection rates of antiplatelet antibodies targeting GPIX, GPIb, GPIIb, GPIIIa, and P-selectin (GMP140) among MYH9-RD, ITP, and healthy control groups. The total antibody positivity rate in MYH9-RD patients was intermediate—significantly higher than in healthy controls (P = 0.0317) but lower than in ITP patients (P = 0.0017).
Conclusion: Significant differences in platelet membrane glycoprotein expression profiles and antiplatelet-specific antibody levels distinguish MYH9-related disorders (MYH9-RD) from immune thrombocytopenia (ITP). These findings have important clinical implications, providing potential biomarkers for the differential diagnosis of MYH9-RD.
Keywords: MYH9-RD, thrombocytopenia, platelet membrane glycoprotein, antiplatelet specific antibodies